Avantor® to Boost Global Production of Single-Use Technologies and Address Growing Biopharma Demand

Increases single-use manufacturing footprint and cleanroom space in the U.S. and Europe

Enables reliable supply of critical materials used in the manufacture of biologics and vaccines

News provided by

Apr 26, 2021, 13:26 ET

RADNOR, Pa., April 26, 2021 /PRNewswire/ -- Avantor Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries, today announced that it will increase global capacity for high-quality single-use technologies used in the production of biologics and vaccines.

In the U.S. and Europe, the Company will increase its single-use manufacturing footprint by 30% and double its cleanroom space. The investment will support growing customer demand for monoclonal antibodies (mAbs), novel cell and gene therapies for oncology and other diseases, as well as vaccines, including those for COVID-19.

Avantor recently expanded its Morrisville, North Carolina, single-use facility and expects completion of a cleanroom expansion at its Devens, Massachusetts, operation by mid-year. The Company also expects to open its second European single-use facility in Hillegom, the Netherlands, by then as well.

Dr. Ger Brophy, Executive Vice President of Biopharma Production at Avantor, said, "The industry's response to the COVID-19 pandemic has relied heavily on the integration of single-use products into biopharma production processes. Efficacy and safety are of the utmost importance to our customers, and they look to us to understand and support their requirements as they rapidly expand their own manufacturing capacity.

"These additions to our global single-use manufacturing ecosystem are critical steps in enabling our customers to get therapies to patients quickly," Brophy added.

The investment further strengthens the Company's single-use network, providing product consistency and capabilities close to bioproduction customers to help ensure efficient and uninterrupted supply.

Watch this video for more information about how Avantor's single-use solutions support biopharma manufacturing.

About Avantor
Avantor®, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve more than 225,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world. For more information, visit avantorsciences.com and find us on LinkedIn, Twitter and Facebook.

Global Media Contact
Robert Donohoe
Senior Director, Corporate Communications
Avantor
M: 484-688-4730
[email protected]

SOURCE Avantor and Financial News